Yeon Hee Park

Jan 21, 2025 | nature.com | Fatima Cardoso |Heather L. McArthur |Javier Cortés |Nadia Harbeck |Melinda L. Telli |David W. Cescon | +3 more

AbstractAddition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab improved outcomes in patients with high-risk, early-stage, triple-negative breast cancer. However, whether the addition of neoadjuvant pembrolizumab to chemotherapy would improve outcomes in high-risk, early-stage, estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2−) breast cancer remains unclear.

Sep 11, 2024 | nature.com | Seock-Ah Im |Javier Cortés |David W. Cescon |Norikazu Masuda |Toshimi Takano |Chiun-Sheng Huang | +6 more

AbstractIn the phase 3 KEYNOTE-355 study (NCT02819518), pembrolizumab plus chemotherapy demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) versus placebo plus chemotherapy among patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) and programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥ 10 tumors.

Aug 23, 2024 | nature.com | Yeon Hee Park

AbstractTrastuzumab emtansine (T-DM1) is widely utilized as a second-line and subsequent treatment for metastatic HER2+ breast cancer and has shown promise in early breast cancer treatment, particularly in adjuvant settings for residual disease after neoadjuvant chemotherapy. However, concerns have arisen regarding long-term hepatic adverse drug reactions (ADRs) not identified in clinical trials.

Aug 20, 2024 | targetedonc.com | Yeon Hee Park

August 20, 2024Yeon Hee Park, MD, discusses the unmet needs in among premenopausal patients with metastatic breast cancer. The Young-PEARL study (NCT02592746) compared exemestane (Aromasin) plus palbociclib (Ibrance) with ovarian function suppression (OFS) to capecitabine in premenopausal women with HR+/HER2– metastatic breast cancer.

Aug 18, 2024 | cancernetwork.com | Joyce O’Shaughnessy |Heather L. McArthur |Javier Cortés |Yeon Hee Park

BackgroundKEYNOTE-756 is a global phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo plus endocrine therapy (ET) in patients with early-stage high-risk estrogen receptor–positive (ER+)/HER2-negative breast cancer. Here, we report primary pathologic complete response (pCR) results and residual cancer burden (RCB) outcomes.